{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T02:04:54Z","timestamp":1772676294258,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T00:00:00Z","timestamp":1707436800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T00:00:00Z","timestamp":1707436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["surg case rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver cancer. Cases when found are often advanced with vascular invasion, and radical resection is often difficult. Despite curative resection, the postoperative recurrence rate of patients with histological lymph node metastasis is high, and their prognosis is poor. Therefore, there is an urgent need to establish multidisciplinary treatment that combines chemotherapy and surgical resection. The efficacy of neoadjuvant chemotherapy (NAC) for locally advanced ICC is unclear. In this report, a case of locally advanced ICC in which pathological complete response (pCR) was achieved after NAC is described.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 79-year-old woman was admitted to a local hospital with appetite loss. Computed tomography showed a 100\u2009\u00d7\u200990\u00a0mm low-contrast tumor in the left hepatic lobe and segment 1 with invasion to the inferior vena cava (IVC), and several lymph nodes along the left gastric artery and lesser curvature were enlarged. Therefore, she was treated with a combined chemotherapy regimen of gemcitabine and cisplatin. After four courses, the tumor size decreased to 30\u2009\u00d7\u200960\u00a0mm without invasion to the IVC. Left hepatectomy extending to segment 1 with bile duct resection combined with middle hepatic vein resection (H1234-B-MHV), dissection of regional lymph nodes and pyloroplasty were performed. After radical resection, pCR was achieved. She is alive with no evidence of disease, 2\u00a0years after surgery.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In this case, a patient with locally advanced ICC achieved pCR to NAC. NAC may be effective for ICC. Patients who achieve pCR may have a better prognosis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40792-024-01832-x","type":"journal-article","created":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T02:25:38Z","timestamp":1707445538000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pathological complete response following neoadjuvant chemotherapy for locally advanced intrahepatic cholangiocarcinoma"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6926-9757","authenticated-orcid":false,"given":"Yoshitaka","family":"Shimamaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isamu","family":"Hosokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsukasa","family":"Takayashiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigetsugu","family":"Takano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itaru","family":"Sonoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Ohtsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,9]]},"reference":[{"key":"1832_CR1","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1080\/13651820801992641","volume":"10","author":"SA Khan","year":"2008","unstructured":"Khan SA, Toledano MB, Taylor-Robinson SD, et al. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford). 2008;10:77\u201382.","journal-title":"HPB (Oxford)"},{"issue":"14","key":"1832_CR2","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273\u201381.","journal-title":"N Engl J Med."},{"key":"1832_CR3","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1097\/SLA.0b013e318236c21d","volume":"254","author":"O Farges","year":"2011","unstructured":"Farges O, Fuks D, Boleslawski E, et al. Influence of surgical margins on outcome in patients with intrahepatic cholangiocarcinoma: a multicenter study by the AFC-IHCC-2009 study group. Ann Surg. 2011;254:824\u20139.","journal-title":"Ann Surg"},{"key":"1832_CR4","doi-asserted-by":"publisher","first-page":"44521","DOI":"10.18632\/oncotarget.17815","volume":"8","author":"A Si","year":"2017","unstructured":"Si A, Li J, Xiang H, et al. Actual over 10-year survival after liver resection for patients with intrahepatic cholangiocarcinoma. Oncotarget. 2017;8:44521\u201332.","journal-title":"Oncotarget"},{"key":"1832_CR5","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1200\/JCO.2011.35.6519","volume":"29","author":"MC de Jong","year":"2011","unstructured":"de Jong MC, Nathan H, Sotiropoulos GC, et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol. 2011;29:3140\u20135.","journal-title":"J Clin Oncol"},{"key":"1832_CR6","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1007\/s00268-005-7761-9","volume":"29","author":"T Nakagawa","year":"2005","unstructured":"Nakagawa T, Kamiyama T, Kurauchi N, et al. Number of lymph node metastases is a significant prognostic factor in intrahepatic cholangiocarcinoma. World J Surg. 2005;29:728\u201333.","journal-title":"World J Surg"},{"key":"1832_CR7","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","volume":"103","author":"T Ohtsuka","year":"2010","unstructured":"Ohtsuka T, Nakachi K, Fukutomi A, et al. Gemcitabin alone or in combination with cisplatin in patients biliary tract cancer: a comparative multicenter in Japan. Br J Cancer. 2010;103:469\u201374.","journal-title":"Br J Cancer"},{"key":"1832_CR8","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/jhbp.1219","volume":"30","author":"T Loka","year":"2023","unstructured":"Loka T, Kanai M, Kobayashi S, et al. Randomized phase III study of gemcitabine, cisplatin plus S-1versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401-MITSUBA). J Hepatobiliary Pancreat Sci. 2023;30:102\u201310.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"1832_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2020.100614","volume":"45","author":"M Fruscione","year":"2021","unstructured":"Fruscione M, Pickens RC, Baker EH, et al. Conversion therapy for intrahepatic cholangiocarcinoma and tumor downsizing to increase resection rates: a systematic review. Curr Probl Cancer. 2021;45: 100614.","journal-title":"Curr Probl Cancer"},{"key":"1832_CR10","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1245\/s10434-015-4768-9","volume":"22","author":"A Kato","year":"2015","unstructured":"Kato A, Shimizu H, Ohtsuka M, et al. Downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer patients treated with gemcitabine plus cisplatin combination therapy followed by radical surgery. Ann Surg Oncol. 2015;22:1093\u20139.","journal-title":"Ann Surg Oncol"},{"key":"1832_CR11","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/j.amjsurg.2021.02.029","volume":"221","author":"TL Sutton","year":"2021","unstructured":"Sutton TL, Billingsley KG, Walker BS, et al. Neoadjuvant chemotherapy is associated with improved survival in patients undergoing hepatic resection for intrahepatic cholangiocarcinoma. Am J Surg. 2021;221:1182\u20137.","journal-title":"Am J Surg"},{"issue":"5","key":"1832_CR12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1477-7819-5-36","volume":"21","author":"MW Slupski","year":"2007","unstructured":"Slupski MW, Szczylik C, Jasinski MK. Unexpected response to systemic chemotherapy in case of primary nonresectable advanced disseminated intrahepatic cholangiocarcinoma. World J Surg Oncol. 2007;21(5):36.","journal-title":"World J Surg Oncol"},{"key":"1832_CR13","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.1007\/s10620-015-3640-x","volume":"60","author":"TB Tran","year":"2015","unstructured":"Tran TB, Bal CK, Schaberg K, et al. Locally advanced intrahepatic cholangiocarcinoma: complete pathologic response to neoadjuvant chemotherapy followed by left hepatic trisectionectomy and caudate lobectomy. Dig Dis Sci. 2015;60:3226\u20139.","journal-title":"Dig Dis Sci"},{"key":"1832_CR14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s13691-018-0327-0","volume":"18","author":"T Tatsuguchi","year":"2018","unstructured":"Tatsuguchi T, Gotoh K, Kobayashi S, et al. Pathologic complete response after. gemcitabine and S-1 chemotherapy for far advanced intrahepatic cholangiocarcinoma. Int Cancer Conf J. 2018;18:93\u20137.","journal-title":"Int Cancer Conf J."},{"key":"1832_CR15","volume":"13","author":"M Abudalou","year":"2021","unstructured":"Abudalou M, Vega EA, Kondratiev S, et al. Complete pathological response to neoadjuvant chemoimmunotherapy in a patient with metastatic intrahepatic cholangiocarcinoma with high tumor mutational burden. Cureus. 2021;13: e20187.","journal-title":"Cureus"},{"key":"1832_CR16","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1097\/SLA.0000000000003468","volume":"270","author":"FI Macedo","year":"2019","unstructured":"Macedo FI, Ryon E, Maithel SK, et al. Survival outcomes associated with clinical and pathological response following neoadjuvant FOLFIRINOX or gemcitabine\/nab-paclitaxel chemotherapy in resected pancreatic cancer. Ann Surg. 2019;270:400\u201313.","journal-title":"Ann Surg"},{"key":"1832_CR17","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1200\/JCO.2007.13.7471","volume":"26","author":"R Adam","year":"2008","unstructured":"Adam R, Wicherts DA, de Haas RJ, et al. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol. 2008;26:1635\u201341.","journal-title":"J Clin Oncol"}],"container-title":["Surgical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40792-024-01832-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40792-024-01832-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40792-024-01832-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T02:28:29Z","timestamp":1707445709000},"score":1,"resource":{"primary":{"URL":"https:\/\/surgicalcasereports.springeropen.com\/articles\/10.1186\/s40792-024-01832-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,9]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1832"],"URL":"https:\/\/doi.org\/10.1186\/s40792-024-01832-x","relation":{},"ISSN":["2198-7793"],"issn-type":[{"value":"2198-7793","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,9]]},"assertion":[{"value":"29 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval is not applicable because this is a case report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written, informed consent was obtained from the patient for publication of this case report and any accompanying images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35"}}